ciprofloxacin fluoroquinolone antibiotic used treat number bacterial includes bone joint infections intraabdominal infections certain types infectious diarrhea respiratory tract infections skin infections typhoid fever urinary tract infections among infections used addition taken mouth eye drops ear drops common side effects include nausea vomiting severe side effects include increased risk tendon rupture hallucinations nerve people myasthenia gravis worsening muscle rates side effects appear higher groups antibiotics cephalosporins lower others studies animals raise concerns regarding use problems identified however children small number women took appears safe secondgeneration fluoroquinolone broad spectrum activity usually results death ciprofloxacin patented introduced world health organizations list essential world health organization classifies ciprofloxacin critically important human available generic prescribed medication united states million ciprofloxacin used treat wide variety infections including infections bones joints endocarditis gastroenteritis malignant otitis externa respiratory tract infections cellulitis urinary tract infections prostatitis anthrax ciprofloxacin treats bacterial infections treat viral infections common cold certain uses including acute sinusitis lower respiratory tract infections uncomplicated gonorrhea ciprofloxacin considered firstline agent ciprofloxacin occupies important role treatment guidelines issued major medical societies treatment serious infections especially likely caused gramnegative bacteria including pseudomonas aeruginosa example ciprofloxacin combination metronidazole one several firstline antibiotic regimens recommended infectious diseases society america treatment communityacquired abdominal infections also features prominently treatment guidelines acute pyelonephritis complicated hospitalacquired urinary tract infection acute chronic certain types certain skin prosthetic joint cases treatment guidelines restrictive recommending cases older narrowerspectrum drugs used firstline therapy less severe infections minimize fluoroquinoloneresistance development example infectious diseases society america recommends use ciprofloxacin fluoroquinolones urinary tract infections reserved cases proven expected resistance narrowerspectrum drugs nitrofurantoin european association urology recommends ciprofloxacin alternative regimen treatment uncomplicated urinary tract infections cautions potential adverse events although approved regulatory authorities treatment respiratory infections ciprofloxacin recommended respiratory infections treatment guidelines due part modest activity common respiratory pathogen streptococcus respiratory quinolones levofloxacin greater activity pathogen recommended first line agents treatment communityacquired pneumonia patients important comorbidities patients requiring hospitalization infectious diseases society america similarly ciprofloxacin recommended firstline treatment acute ciprofloxacin approved treatment gonorrhea many countries recommendation widely regarded obsolete due resistance united states ciprofloxacin pregnancy category category includes drugs adequate wellcontrolled studies human pregnancy exist animal studies suggested potential harm fetus potential benefits may warrant use drug pregnant women despite potential risks expert review published data experiences ciprofloxacin use pregnancy teratogen information system concluded therapeutic doses pregnancy unlikely pose substantial teratogenic risk quantity quality datafair data insufficient state risk exposure quinolones including levofloxacin firsttrimester associated increased risk stillbirths premature births birth defects low birth two small postmarketing epidemiology studies mostly shortterm firsttrimester exposure found fluoroquinolones increase risk major malformations spontaneous abortions premature birth low birth label notes however studies insufficient reliably evaluate definitive safety risk less common defects ciprofloxacin pregnant women developing fetuses fluoroquinolones reported present mothers milk thus passed nursing us food drug administration fda recommends risk serious adverse reactions including articular damage infants nursing mothers taking ciprofloxacin decision made whether discontinue nursing discontinue drug taking account importance drug mother oral intravenous ciprofloxacin approved fda use children two indications due risk permanent injury musculoskeletal system currentwhen recommendations american academy pediatrics note systemic use ciprofloxacin children restricted infections caused multidrugresistant pathogens safe effective alternatives spectrum activity includes strains bacterial pathogens responsible communityacquired pneumonias bronchitis urinary tract infections ciprofloxacin particularly effective gramnegative bacteria escherichia coli haemophilus influenzae klebsiella pneumoniae legionella pneumophila moraxella catarrhalis proteus mirabilis pseudomonas aeruginosa less effective grampositive bacteria methicillinsensitive staphylococcus aureus streptococcus pneumoniae enterococcus faecalis newer result widespread use treat minor infections readily treatable older narrowerspectrum antibiotics many bacteria developed resistance drug recent years leaving significantly less effective would resistance ciprofloxacin fluoroquinolones may evolve rapidly even course treatment numerous pathogens including enterococci streptococcus pyogenes klebsiella pneumoniae quinoloneresistant exhibit widespread veterinary usage fluoroquinolones particularly europe meanwhile burkholderia cepacia clostridium innocuum enterococcus faecium strains developed resistance ciprofloxacin varying fluoroquinolones become class antibiotics commonly prescribed adults nearly half prescriptions us conditions approved fda acute bronchitis otitis media acute upper respiratory tract infection according study supported part agency healthcare research additionally commonly prescribed medical conditions even bacterial begin viral infections proven benefit existed contraindications ciprofloxacin also considered contraindicated children except indications outlined pregnancy nursing mothers people epilepsy seizure disorders caution may required people marfan syndrome ehlersdanlos adverse effects involve tendons muscles joints nerves central nervous rates adverse effects appear higher groups antibiotics cephalosporins lower others compared antibiotics studies find higher rate adverse others find clinical trials adverse events described mild moderate severity abated soon drug discontinued required adverse effects may ciprofloxacin stopped adverse event people treated medication mouth frequently reported drugrelated events trials formulations dosages drugtherapy durations indications nausea diarrhea abnormal liver function tests vomiting rash adverse events occurred rates ciprofloxacin includes boxed warning united states due increased risk tendinitis tendon rupture especially people older years people also use corticosteroids people kidney lung heart tendon rupture occur therapy even months discontinuation one study found fluoroquinolone use associated increase tendon problems risk increased years age age also taking corticosteroids among quinolone users study cases achilles tendon rupture fluoroquinolones including ciprofloxacin associated increased risk cardiac toxicity including qt interval prolongation torsades de pointes ventricular arrhythmia sudden ciprofloxacin lipophilic ability cross fda label warns nervous system effects ciprofloxacin like fluoroquinolones known trigger seizures lower seizure threshold may cause central nervous system adverse effects headache dizziness insomnia reported occurring fairly commonly postapproval review articles along much lower incidence serious cns adverse effects tremors psychosis anxiety hallucinations paranoia suicide attempts especially higher like fluoroquinolones also known cause peripheral neuropathy may irreversible weakness burning pain tingling ciprofloxacin active six eight vitro assays used rapid screens detection genotoxic effects active vivo assays longterm carcinogenicity studies rats mice resulted carcinogenic tumorigenic effects due ciprofloxacin daily oral dose levels mgkg rats mice respectively times highest recommended therapeutic dose based upon results photo cocarcinogenicity testing indicate ciprofloxacin reduce time appearance uvinduced skin tumors compared vehicle black box warning ciprofloxacin used people myasthenia gravis due possible exacerbation muscle weakness may lead breathing problems resulting death ventilator support fluoroquinolones known block neuromuscular concerns fluoroquinolones including ciprofloxacin affect cartilage young clostridium difficileassociated diarrhea serious adverse effect ciprofloxacin fluoroquinolones unclear whether risk higher broadspectrum wide range rare potentially fatal adverse effects reported us fda subject case reports includes aortic toxic epidermal necrolysis syndrome low blood pressure allergic pneumonitis bone marrow suppression hepatitis liver failure sensitivity medication discontinued rash jaundice sign hypersensitivity children elderly much greater risk experiencing adverse overdose ciprofloxacin may result reversible renal toxicity treatment overdose includes emptying stomach induced vomiting gastric lavage well administration antacids containing magnesium aluminium calcium reduce drug absorption renal function urinary ph monitored important support includes adequate hydration urine acidification necessary prevent crystalluria hemodialysis peritoneal dialysis remove less ciprofloxacin may quantified plasma serum monitor drug accumulation patients hepatic dysfunction confirm diagnosis poisoning acute overdose ciprofloxacin interacts certain foods several drugs leading undesirable increases decreases serum levels distribution one drugs ciprofloxacin taken antacids containing magnesium aluminum highly buffered drugs sevelamer lanthanum carbonate sucralfate didanosine supplements containing calcium iron zinc taken two hours six hours products magnesium aluminum antacids turn ciprofloxacin insoluble salts readily absorbed intestinal tract reducing peak serum concentrations leading therapeutic failure additionally taken dairy products calciumfortified juices alone peak serum concentration area serum concentrationtime curve reduced however ciprofloxacin may taken dairy products calciumfortified juices part ciprofloxacin inhibits drugmetabolizing enzyme thereby reduce clearance drugs metabolized enzyme substrates exhibit increased serum levels ciprofloxacintreated patients include tizanidine theophylline caffeine methylxanthines clozapine olanzapine ropinirole coadministration ciprofloxacin substrate tizanidine zanaflex contraindicated due increase peak serum concentrations tizanidine administered ciprofloxacin compared administration tizanidine alone use ciprofloxacin cautioned patients theophylline due narrow therapeutic index authors one review recommended patients treated ciprofloxacin reduce caffeine intake evidence significant interactions several substrates cyclosporine equivocal committee safety medicines fda warn central nervous system adverse effects including seizure risk may increased nsaids combined mechanism interaction may involve synergistic increased antagonism gaba altered serum levels antiepileptic drugs phenytoin carbamazepine increased decreased reported patients receiving concomitant ciprofloxacin potent inhibitor ciprofloxacin broadspectrum antibiotic fluoroquinolone class active grampositive many gramnegative functions inhibiting type ii topoisomerase dna gyrase topoisomerase necessary separate bacterial dna thereby inhibiting cell division bacterial dna fragmentation occur result inhibition enzymes ciprofloxacin systemic administration available immediaterelease tablets extendedrelease tablets oral suspension solution intravenous administration administered one hour intravenous ciprofloxacin rapidly distributes tissues levels tissues exceeding serum penetration central nervous system relatively modest cerebrospinal fluid levels normally less peak serum concentrations serum halflife ciprofloxacin hours administered dose excreted urine unmetabolized drug additional excreted urine metabolites urinary excretion virtually complete hours administration dose adjustment required elderly renal ciprofloxacin weakly bound serum proteins inhibitor drugmetabolizing enzyme cytochrome leads potential clinically important drug interactions drugs metabolized ciprofloxacin orally available administered orally slightly higher dose needed achieve exposure switching iv oral extended release oral allow oncedaily administration releasing drug slowly gastrointestinal tract tablets contain administered dose immediaterelease form slowrelease matrix maximum serum concentrations achieved hours administration compared immediaterelease tablets xr tablets provide higher cmax aucs equivalent ciprofloxacin immediaterelease tablets contain ciprofloxacin hydrochloride salt xr tablets contain mixture hydrochloride salt free ciprofloxacin acid empirical formula molecular weight gmol faintly yellowish light yellow crystalline ciprofloxacin hydrochloride usp monohydrochloride monohydrate salt ciprofloxacin faintly yellowish light yellow crystalline substance molecular weight gmol empirical formula ciprofloxacin widely used secondgeneration million prescriptions written making prescribed generic drug prescribed antibacterial first members quinolone antibacterial class relatively lowpotency drugs nalidixic acid used mainly treatment urinary tract infections owing renal excretion propensity concentrated publication filed pharmaceutical arm kyorin seiyaku kabushiki kaisha disclosed discovery norfloxacin demonstration certain structural modifications including attachment fluorine atom quinolone ring leads dramatically enhanced antibacterial aftermath disclosure several pharmaceutical companies initiated research development programs goal discovering additional antibacterial agents fluoroquinolone class fluoroquinolone program bayer focused examining effects minor changes norfloxacin company published vitro potency data ciprofloxacin fluoroquinolone antibacterial chemical structure differing norfloxacin presence single carbon small change led two increase potency strains gramnegative bacteria importantly structural change led fourfold improvement activity important gramnegative pathogen pseudomonas aeruginosa making ciprofloxacin one potent known drugs treatment intrinsically antibioticresistant pathogenmedical citation needed oral tablet form ciprofloxacin approved october one year approval intravenous formulation introduced ciprofloxacin sales reached peak billion euros bayers patent expired annual sales averaged around name probably originates international scientific nomenclature ci alteration cycl propyl fluor ox az available generic medication expensive least one company turtle pharma private limited provides industrialsize october prescription access litigation pal project filed suit dissolve agreement bayer three competitors produced generic versions drugs barr laboratories rugby laboratories hoechstmarionroussel pal claimed blocking access adequate supplies cheaper generic versions ciprofloxacin plaintiffs charged bayer corporation unit bayer ag unlawfully paid three competing companies total million prevent cheaper generic versions ciprofloxacin brought market well manipulating price supply numerous consumer advocacy groups joined lawsuit october five years bayers patent expired united states district court eastern district new york granted bayers defendants motion summary judgment holding anticompetitive effects caused settlement agreements bayer codefendants within exclusionary zone patent thus could redressed federal antitrust effect upholding bayers agreement competitors ciprofloxacin systemic administration available immediaterelease tablets extendedrelease tablets oral suspension solution intravenous infusion also available local administration eye drops ear drops class action filed bayer ag behalf employees brentwood post office washington dc workers us capitol along employees american media inc florida postal workers general alleged developed serious adverse effects taking ciprofloxacin aftermath anthrax attacks action alleged bayer failed warn class members potential side effects drug thereby violating pennsylvania unfair trade practices consumer protection laws class action defeated litigation abandoned similar action filed new jersey four new jersey postal workers withdrawn lack grounds workers informed risks ciprofloxacin given option taking resistance ciprofloxacin grown since introduction research conducted discover develop analogs effective resistant bacteria looked antiviral models httpsenwikipediaorgwikiciprofloxacin